Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
December 06, 2024 08:00 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
December 03, 2024 07:30 ET
|
Aptose Biosciences, Inc.
Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations
AML and KYC: Anti-Money Laundering & Know Your Customer Training Course - Prevention, Detection and Investigation of Financial Crime (ONLINE EVENT: December 10, 2024)
December 02, 2024 04:01 ET
|
Research and Markets
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "AML and KYC - Anti-Money Laundering & Know Your Customer Training" training has been added to ResearchAndMarkets.com's offering. During this...
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
November 12, 2024 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host...
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
November 07, 2024 16:05 ET
|
Vor Biopharma
Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed as...
Kura Oncology Reports Third Quarter 2024 Financial Results
November 07, 2024 16:05 ET
|
Kura Oncology, Inc.
– Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in...
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
November 05, 2024 09:09 ET
|
Kura Oncology, Inc.
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th – – Ziftomenib combined with ven/aza in R/R NPM1-m or KMT2A-r...
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against The Toronto-Dominion Bank (NYSE: TD); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel
October 29, 2024 18:36 ET
|
DiCello Levitt LLP
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of all persons and entities who purchased or otherwise acquired The Toronto-Dominion Bank (NYSE: TD)...
Lucinity and Facctum Partner for AI-Powered, Real-Time Watchlist Screening and Investigations
October 08, 2024 07:43 ET
|
Lucinity
Lucinity and Facctum Partner for AI-Powered, Real-Time Watchlist Screening and Investigations
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
September 30, 2024 07:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new...